![](/fileadmin/_processed_/csm_RNA_IQVIA_18a4c7238b.png)
Wacker Chemie AG opens €100m RNA manufacturing site
With a new production facility, which Wacker Chemie subsidiary Wacker Biotech calls an RNA competence centre and whose construction costs are...
![](/fileadmin/_processed_/csm_Obstructive_Sleep_Apnea_Treatment_Genio_by_Nyxoah_083756dfdb.png)
Nyxoah signs a €37.5m loan with the European Investment Bank
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), located in Mont-Saint-Guibert, Belgium announced that it has signed a €37.5m loan facility agreement with...
![](/fileadmin/_processed_/csm_SBA__c__Elvin_YilmazElvin_Yilmaz.jpg__a5edabbb67.jpg)
Swiss Biotech Report reporting record turnover
The Swiss Biotech Report 2024 commissioned by the Swiss Biotech Association and co-published with EY on the occasion of the Swiss Biotech Day...
![](/fileadmin/_processed_/csm_Biotalys_platform_b35a9cfabc.png)
Biotalys starts field testing for biofungicide
The protein-based biofungicide is under development of the company’s Agrobody technology platform for sustainable biocontrols as an alternative...
![](/fileadmin/_processed_/csm_Iqvia-obesity_pipeline_0680784a7f.png)
AstraZeneca puts step into obesity market
SixPeaks Bio, launched with US$30m in Series A funding led by Versant Ventures, which is known for its build to buy strategy, and announced a...
![](/fileadmin/_processed_/csm_Catalym_eb_68929d20e3.png)
Catalym raises US$150m
The aim in four Phase IIb trials starting in 2025 is to demonstrate the efficacy, safety and licensing potential of Visugromab plus Nivolumab in...
![](/fileadmin/Content/NewsAndStories/2024/Enk_freitag.png)
Friday: CRISPR screen highlights genes behind T cell plasticity in autoimmunity
Pro-inflammatory CD4-positive T cells are major drivers of autoimmune diseases, yet therapiesmodulating T cell phenotypes to promote an...